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The Generation of Influenza-Specific Humoral Responses Is
Impaired in ST6Gal I-Deficient Mice1
Junwei Zeng,2* Hye Mee Joo,2* Bheemreddy Rajini,* Jens P. Wrammert,† Mark Y. Sangster,*
and Thandi M. Onami3*
Posttranslational modification of proteins, such as glycosylation, can impact cell signaling and function. ST6Gal I, a glycosyl-
transferase expressed by B cells, catalyzes the addition of -2,6 sialic acid to galactose, a modification found on N-linked glyco-
proteins such as CD22, a negative regulator of B cell activation. We show that SNA lectin, which binds -2,6 sialic acid linked to
galactose, shows high binding on plasma blasts and germinal center B cells following viral infection, suggesting ST6Gal I expres-
sion remains high on activated B cells in vivo. To understand the relevance of this modification on the antiviral B cell immune
response, we infected ST6Gal I/ mice with influenza A/HKx31. We demonstrate that the loss of ST6Gal I expression results in
similar influenza infectivity in the lung, but significantly reduced early influenza-specific IgM and IgG levels in the serum, as well
as significantly reduced numbers of early viral-specific Ab-secreting cells. At later memory time points, ST6Gal I/ mice show
comparable numbers of IgG influenza-specific memory B cells and long-lived plasma cells, with similarly high antiviral IgG titers,
with the exception of IgG2c. Finally, we adoptively transfer purified B cells from wild-type or ST6Gal I/ mice into B cell-
deficient (MT/) mice. Recipient mice that received ST6Gal I/ B cells demonstrated reduced influenza-specific IgM levels,
but similar levels of influenza-specific IgG, compared with mice that received wild-type B cells. These data suggest that a B cell intrinsic
defect partially contributes to the impaired antiviral humoral response. The Journal of Immunology, 2009, 182: 4721–4727.
H umoral immunity is characterized by prolonged Ab pro-duction, even after resolution of infection, in stark con-trast to the T cell response, where effector T cell function
is relatively short-lived. Abs, by neutralizing or opsonizing free
extracellular pathogens, serve as a critical first-line defense against
infection. Humoral immunity is comprised of pre-existing Ab pro-
duced by Ab-secreting cells (ASCs)4 termed long-lived plasma
cells (LLPCs), as well as a population of memory B cells (MBCs)
that can differentiate following antigenic stimulation into plasma
cells (1–4).
The enzyme ST6Gal I is a glycosyltransferase highly expressed
by B and T cells that synthesizes the glycan sequence -2,6 sialic
acid linked to galactose (Sia2-6Gal) (5). This structure is typi-
cally found on N-linked glycans of glycoproteins, such as the
mammalian lectin CD22, a transmembrane glycoprotein expressed
by B cells that has high specificity for (Sia2-6Gal). CD22 has
been shown to be a negative regulator of B cell signaling by re-
cruiting SHP-1 to the BCR, thus attenuating signals via the BCR
(5–7). The plant lectin Sambucas nigra agglutinin (SNA) binds the
product of ST6Gal I, Sia2-6Gal, so SNA lectin binding can be
used as an indicator of ST6Gal I expression and/or activity (5).
ST6Gal I null mice were initially described several years ago
(5). These mice demonstrate normal T cell activation to anti-CD3
cross-linking in vitro, but defective BCR signaling in vitro, and
reduced Ab production following immunization with T-indepen-
dent and T-dependent Ags (DNP-Ficoll or DNP-keyhole limpet
hemocyanin) in vivo (5). However, despite indications that B cell
immune function may be compromised in these mice, as well as
evidence that addition of cytokines could abrogate in vitro B cell
proliferation differences, no studies have documented whether or
not protective Ab and memory B cell responses are compromised
in these mice when exposed to pathogenic microorganisms such as
live viral infection.
In this study, we have compared the outcome of influenza viral
infection of wild-type or ST6Gal I-deficient mice. The hemagglu-
tinin (HA) glycoprotein plays a key role in influenza pathogenicity
and is involved in host-cell recognition (8). First, we show that
effective replication of influenza A/HKx31 (Orthomyxoviridae, in-
fluenza A) does occur in the lungs of ST6Gal I/ mice; however,
these mice demonstrate defective early influenza-specific B cell
responses. Next, we determine that expansion of CD4 and CD8
influenza-specific T cell numbers in the lung and lymph nodes is
normal in ST6Gal I/ mice. Furthermore, we demonstrate similar
overall numbers of influenza specific IgG MBCs and LLPCs, al-
though we note both a reduction in serum levels of influenza spe-
cific IgG2c and IgG2c-producing LLPCs in the bone marrow. Fi-
nally, we demonstrate an impaired influenza specific IgM response
in B cell-deficient mice that receive ST6Gal I/ B cells, suggest-
ing that a B cell intrinsic defect partially contributes to the im-
paired humoral response. Overall, our findings suggest that lack of
ST6Gal I expression appears to prominently impair the generation
of a viral-specific humoral response but plays a lesser role in in-
fluenza-specific memory.
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ST6Gal I-deficient mice were generated by J. Marth (University of Cali-
fornia, San Diego, La Jolla, CA) and obtained from the Consortium for
Functional Glycomics and bred in-house (5). C57BL/6 female mice and
B6.129S2-Igh-6tm1Cgn/J (MT/ mice) were purchased from The Jackson
Laboratory. Mice were maintained under specific pathogen-free conditions
at the University of Tennessee in accordance with university IACUC
guidelines and used at 6–12 wk of age. Anesthetized mice were intrana-
sally infected with 106.8 EID50 influenza A/HKx31 in 30 l of PBS as
described previously (9, 10). MT/ mice were primed with 107.4 EID50
influenza A/HKx31 i.p.
Tissue harvest and flow cytometry
At specified time points (days 7, 10, 40 postinfection (p.i.)), animals were
sacrificed, and tissues were harvested for viral titer (lungs only), immuno-
fluorescence, or isolation of lymphocytes. For isolation of lymphocytes
from lungs, lungs were perfused with 5 ml of cold PBS before removal and
processed as described previously (11). Single-cell suspensions were
stained with mAbs purchased from BD Pharmingen (CD4, CD8, CD44,
B220, CD138, FAS, GL7, IFN-, and TNF-), Vector Laboratories (SNA
lectin and peanut agglutinin (PNA)), or Southern Biotechnology Associates
(IgD). Intracellular cytokine staining was assayed on cells from spleen,
lung, and MedLN. All samples were run on a FACSCalibur (BD Bio-
sciences). All data were analyzed with FlowJo software (Tree Star). Un-
paired Student’s t tests were performed to determine statistical significance
with * denoting p  0.05, ** denoting p  0.01, and *** denoting p 
0.001.
Immunofluorescence
MedLNs were removed from mice on day 7 p.i. and frozen in OCT at
80°C. The frozen tissues were cut at 8-m thickness, thaw-mounted onto
slides, air-dried, and fixed in cold acetone for 10 min. The sections were
then blocked with 3% BSA and stained for germinal centers with PNA-
FITC (Vector Laboratories), anti-B220-PE, and/or GL7-FITC (BD Pharm-
ingen) as indicated. After staining, sections were washed with PBS,
mounted using Vectashield mounting medium (Vector Laboratories), and
analyzed using a laser scanning confocal microscope (Leica SP2).
Influenza viral titer determination
Lungs were collected on indicated days p.i. and homogenized in Hanks’
media with 0.1% BSA (Life Technologies). Eight replicates of the homog-
enized lung were serially diluted 10-fold across 96-well U-bottom plates in
1 MEM with 0.3% BSA, 1 g/ml N-p-tosyl-L-phenylalanine chloro-
methyl ketone-treated trypsin (Worthington), penicillin (100 IU/ml), strep-
tomycin (100 g/ml), and 5% FBS. The titrated lung samples were added
to serum-free MEM on a Madin-Darby canine kidney cell monolayer pre-
pared in 96-well tissue culture plates and incubated for 48 h at 37°C and
5% CO2. Wells that were positive for viral growth were identified by test-
ing supernatants for hemagglutinating activity using 0.5% chicken RBCs.
ELISPOT assay to detect influenza specific ASCs
A preparation of concentrated viral particles was disrupted for 10 min at
room temperature in a 1/10 dilution of disruption buffer (0.5% Triton
X-100, 0.6 M KCl, and 0.05 M Tris-HCl (pH 7.5)) in PBS, further diluted
in PBS, and plated at 1 g/well in nitrocellulose-bottomed 96-well Mul-
tiscreen HA filtration plates (Millipore). After overnight incubation at 4°C,
plates were washed with PBS, and blocked with cell culture medium con-
taining 10% FBS. Plates were emptied by flicking, and cell suspensions
(including resuspended cells from 96-well MBC assay plates) were added
in volumes of 100 l/well. After incubation for 3–4 h at 37°C in a
humidified atmosphere containing 5% CO2, plates were thoroughly washed
with PBS alone and PBS containing 0.1% Tween 20. Alkaline phospha-
tase-conjugated goat anti-mouse IgG, IgM, or IgA (Southern Biotechnol-
ogy Associates) diluted to 2 g/ml in PBS containing 5% BSA was added
(100 l/well), and the plates were incubated overnight at 4°C. The plates
were then washed extensively with PBS alone and PBS containing 0.1%
Tween 20, including washing the underside of the nitrocellulose filters.
Spots were developed at room temperature by the addition of 1 mg/ml
5-bromo-4-chloro-3-indolyl phosphate (Sigma-Aldrich) in diethanolamine
buffer (10% diethanolamine, 0.1 M NaCl, 5 mM MgCl2, and 0.1 M Tris
HCl (pH 9.5)) in 100 l/well. After spot development, plates were washed
with PBS, dried, and spots representing individual ASCs were counted
using an Olympus SZX9 stereozoom microscope.
Memory B cell assay
Influenza-specific MBC frequencies were determined by a previously de-
scribed LDA based on in vitro stimulation of MBCs to differentiate into
ASCs (10, 12). Briefly, 2-fold dilutions of cells were incubated in 96-well
tissue culture plates (routinely 12 wells per dilution), together with 106
irradiated (3000 rad) syngeneic naive spleen cell feeders plus -propiolac-
tone-inactivated HKx31 (Charles River Laboratories). After incubation,
cells in each well were transferred to ELISPOT plates for the enumeration
of influenza-specific IgG ASCs. Pre-existing virus-specific ASC numbers
at the time of sampling were determined by direct ex vivo ELISPOT assay.
After in vitro MBC activation and ELISPOT analysis, individual wells
were scored positive for virus-specific MBC if progeny ASC numbers were
greater than twice the mean pre-existing ASCs. The virus-specific MBC
frequency was calculated from the number of negative wells per cell di-
lution by extrapolation to the dilution that gave 37% negative wells (12).
Linearity between the proportion of negative cultures and the input cell
dose indicated direct measurement of MBC. No influenza-specific IgG
ASCs were detected after in vitro stimulation of lymphocytes from naive
mice or from mice infected intranasally 8 wk previously with an unrelated
virus.
B cell transfer and ELISA
MACS B220 beads (Miltenyi Biotec) were used for purification of B cells
according to the manufacturer’s instructions. Purity of B220 B cells was
95% determined by FACS. B220 spleen cells (2  107) were adoptively
FIGURE 1. Binding of SNA on B cell populations. Splenocytes from
uninfected C57BL/6 mice or mice infected with 2  105 PFU of LCMV
Armstrong i.p. either 8 or 15 days earlier were used for the analysis. The
left panel in B–D shows the gating, and the right panel shows SNA binding
as histograms of the gated population. A, Cartoon depicting the glycosyl-
transferase ST6Gal I, which catalyzes addition of terminal 2,6 sialic acids
to galactose. SNA lectin binds Sia2-6Gal1-4GlcNac. B, Naive B cells
from uninfected mice gated on B220/IgD cells, or CD138/B220low
plasma blasts on day 8 (C), or B220FAS/IgD germinal center cells (D)
all show high SNA binding.
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transferred into individual primed MT-deficient mice i.v. followed by
infection with influenza i.n. 24 h later. For serum Ab determination by
ELISA, plates were coated with purified, detergent disrupted influenza
A/HKx31 virus (0.5 g/well) and incubated at 4°C overnight. Plates were
washed with PBS-Tween 20 (0.05%), blocked with PBS/FBS (3%), and
washed again. Serial 3-fold serum dilutions were prepared in PBS-Tween
20 (0.05%)-BSA (0.5%). The plates were incubated at room temperature
4 h or overnight at 4°C, then washed thoroughly. Plate-bound secreted Abs
were detected using alkaline phosphatase-conjugated goat anti-mouse Abs
with specificity for IgM, IgG, IgG1, IgG2b, IgG2c, or IgG3 (Southern
Biotechnology Associates) diluted in PBS-BSA (1%). After 4 h of incu-
bation at room temperature, plates were washed extensively, and color
FIGURE 2. Influenza-specific B cell responses in ST6Gal I/ mice during acute infection. B6 or ST6Gal I/ mice were infected with influenza
A/HKx31 i.n. and bled on indicated days. Serum virus-specific IgM (left) and IgG (right) (A) and IgG (B) isotypes on day 7 were measured by ELISA.
Data are expressed as the reciprocal endpoint Ab titer on serial titration of influenza Ab. C, Cell suspensions of CLN, MedLN, and spleen were prepared
from individual mice on day 7 p.i., and the ELISPOT assay was used to measure the number of cells producing virus-specific IgM, IgG1, IgG2b, IgG2c,
IgG3 or IgA as indicated, with n  6–8 mice/group. Results are expressed as the number of ASC/105 nucleated cells. ( indicates p  0.05,  indicates
p  0.01, and  indicates p  0.001.)
FIGURE 3. Germinal center B cells of ST6Gal I/ mice do not bind GL7. Mice were infected with influenza x31 intranasally, and on day 7 p.i., lymph
nodes were isolated and either frozen for immunofluorescence or stained for FACS analysis using germinal center or plasma cell markers. Numbers show
percentages of gated population. A, Immunofluorescence staining of MedLN using B220 and GL7 or B220 and PNA as indicated. B220 in red and GL7
or PNA staining in green. B, FACS analysis of germinal center B cells in CLN of same mice, gating on IgDlowB220 cells. Histogram shows GL7 binding
on gated IgDlowB220 cells. Dot plot shows PNAhighFas cell population of gated IgDlowB220 cells. C, FACS analysis of plasma cells in CLN gating
on CD138B220 cells. Histogram overlay of SNA binding of gated population. Filled histogram shows ST6Gal I/, and open histogram shows B6. Bar
graph shows frequencies of total plasma cells in indicated mice. D, Total number of germinal center B cells in CLN gating on IgDlowB220PNAhighFas
or IgDlowB220GL7 cells. Bar graphs show data from n  5 mice. (, p  0.05; and , p  0.01.)
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development with p-nitrophenyl phosphate (Sigma-Aldrich) in diethanol-
amine buffer was read at 405 nm using a Synergy2 MultiDetection Micro-
plate Reader (Bio-Tek Instruments). The virus-specific serum Ab titer is ex-
pressed as the reciprocal of the highest dilution giving an absorbance value
more than twice that for simultaneously titrated samples from naive mice.
Results
SNA binding is high on naive and in vivo activated B cells
The plant lectin SNA preferentially binds 2-6-linked sialic acids
and previous reports have demonstrated high SNA binding on
naive lymphocytes that is abrogated in lymphocytes lacking
ST6Gal I expression (5). Gene expression studies comparing naive
B cells to in vitro activated B cells revealed that ST6Gal I expres-
sion remains high on activated B cells (13).
We examined SNA lectin binding by flow cytometry on B cells
following in vivo B cell activation (Fig. 1). We observed that on
day 8 following viral infection, B220CD138 plasma blasts re-
main SNA high similar to B220IgD naive B cells in uninfected
mice. Additionally, on day 15 p.i., B220FasgDlow germinal
center B cells also show high SNA lectin binding (Fig. 1).
Impaired generation of influenza-specific humoral responses in
ST6Gal I-deficient mice
To examine the functional relevance of this modification for anti-
viral humoral responses, we obtained ST6Gal I-null mice. ST6Gal
I/ mice develop normally and show a normal lymphoid com-
partment and architecture (5, 14). However, B cells from ST6Gal
I/ mice show impaired proliferation in vitro to anti-IgM, anti-
CD40, and LPS stimulation that can be rescued by the addition of
IL-4 or gene ablation of CD22 (5, 6, 15). These mice also show
defective T-dependent and T-independent humoral responses to
hapten-protein immunization. Previous studies examining Ab re-
sponses following viral infection have sometimes contrasted with
results using hapten-protein immunizations (16, 17). We infected
ST6Gal I/ mice with influenza A/HKx31 and serially bled them
to determine influenza-specific IgM and IgG by serum ELISA
(Fig. 2A). We observed 10-fold reductions and 5-fold reduc-
tions in the levels of influenza-specific IgM and IgG, respectively,
on day 7 p.i. (Fig. 2A). Analysis of IgG isotypes on day 7 p.i.
revealed that all isotypes were significantly reduced compared
with wild-type mice, with IgG3 and IgG2c showing the most im-
pairment of the IgG isotypes (3- and 7-fold, respectively; Fig. 2B).
By day 14 p.i., influenza-specific IgG was similar comparing wild-
type and ST6Gal I/ mice, while influenza-specific IgM still re-
mained impaired.
One possible explanation for the differences observed could be
aberrantly glycosylated Abs are preferentially scavenged in vivo
by lectin-bearing macrophages (18). We determined whether
ST6Gal I/ mice are defective in the generation of viral-specific
plasma cells (Fig. 2C). Examination of influenza-specific ASCs by
ELISPOT in the CLN, the MedLN, and spleen show significantly
reduced numbers at day 7. Influenza-specific IgM producing ASCs
showed the most impairment, especially in the spleen. Influenza-
specific IgA producing ASCs were reduced, but the reduction was
not statistically significant (Fig. 2C). These results show that the
reduced serum levels of antiviral Abs are likely not the effect of
preferential scavenging by macrophages, but rather a defect in the
generation of the humoral immune response.
Germinal centers of ST6Gal I/ mice do not bind GL7
To determine whether any differences in germinal center formation
are present in ST6Gal I/ mice, we performed immunostaining in
the lymph nodes. Our analysis of the MedLN by immunofluores-
cence on day 7 p.i. revealed that germinal center B cells in ST6Gal
I/ mice show no expression of the germinal center marker GL7,
but show high binding by the PNA lectin (Fig. 3A). These data are
consistent with results demonstrating that the mAb GL7 shows
specificity for a sialylated glycan epitope expressed on germinal
center B cells (19). FACS analysis of lymphocytes from the CLN
of these mice gating on IgDlowB220 cells showed similar per-
centages and numbers of GC cells as measured by expression of
germinal center markers Fas and PNA, and confirmed loss of GL7
binding (Fig. 3, B and D). We also noted that the mean fluores-
cence intensity of PNA binding was significantly higher in ST6Gal
I/ GC cells compared with wild-type (mean fluorescence inten-
sity  1178 vs 549). The frequencies of total plasma cells
(CD138B220) were reduced in ST6Gal I/ mice, consistent
FIGURE 4. Influenza viral infection and clearance in lungs. B6 and
ST6Gal I/ mice were infected intranasally, and on indicated days postin-
fection, lungs were collected and assayed for influenza viral titer. Filled
symbols are B6 mice, and open symbols are ST6Gal I/ mice. Each
symbol represents one mouse tested. The limit of detection is shown by the
dotted line.
FIGURE 5. Influenza-specific T cell responses. At day 10 p.i., lympho-
cytes from MedLN and lung were stimulated with indicated peptides for
5 h and stained for intracellular cytokine production of IFN-. A, Repre-
sentative staining for each tissue gating on CD4 or CD8 T cells. Numbers
indicate the percentage of CD4 or CD8 T cells specific for each peptide. B,
Total NP311-325-specific CD4 or NP366-374-specific CD8 T cells were
enumerated in MedLN and lung at day 10; n  4 mice in each group.
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with the reduction in viral specific ASCs and as expected, showed
no binding of the SNA lectin (Figs. 2C and 3C).
Productive infection and replication of influenza in
ST6Gal I/ mice
Entry of influenza virus, as well as the productive infection and
replication in lung epithelial cells is dependent on sialic acid mod-
ification of glycoproteins. Productive influenza infection in hu-
mans depends specifically on sialyloligosaccharides containing
terminal N-acetyl sialic acid linked to galactose by an 2,6-link-
age, whereas in mice the data suggest 2,3-linked sialic acids are
important (20, 21). Influenza viral titers were determined in the
lungs of mice infected with A/HKx31 (Fig. 4). We confirm that
similar to wild-type mice, lungs from ST6Gal I/ mice become
productively infected with influenza A/HKx31 and show compa-
rable viral titers at days 3 and 5 p.i. By day 7 p.i., we see a trend
toward higher viral titers in the lungs of ST6Gal I/ mice, which
coincides with the early impairment of viral-specific Ab responses
observed in these mice. However, this difference is not statistically
significant ( p  0.07), and by day 10 virus was cleared by both
wild-type and ST6Gal I/ mice. These results extend the findings
in a recently published report showing several human influenza A
viruses are able to productively infect the respiratory tract of mice
lacking ST6Gal I expression (22).
Viral-specific CD4 and CD8 T cells in the lungs and MedLN
Since T cells also express ST6Gal I, we enumerated influenza-
specific T cells isolated from the lungs or draining nodes (MedLN)
of wild-type or ST6Gal I/ mice on day 10 using CD4-specific
(NP311-325) or CD8-specific (NP366–374) peptides performing
intracellular cytokine staining to detect IFN- (23). ST6Gal I/
mice generate similar numbers of viral-specific CD4 and CD8 T
cells in the lung and MedLN, show similar coproduction of TNF-
and IL-2, and show similar numbers of CD44high CD4 and CD8 T
cells in these tissues (Fig. 5 and data not shown). However, we did
note reduced numbers of viral specific CD8 T cells in the spleen on
day 10 consistent with our observations of reduced viral specific T
cells following LCMV infection in these mice (T. Onami, manu-
script in preparation).
Viral-specific memory B cell responses
ST6Gal I/ mice control influenza infection by day 10, despite
impaired influenza-specific humoral responses (Fig. 4). The strong
antiviral T cell responses in the lungs of these mice likely con-
tribute to this effective viral clearance. Immune ST6Gal I/ mice
show high levels of class-switched IgG Ab; however, a significant
reduction in serum levels of IgG2c was observed, supported by a
significant reduction in frequencies of influenza-specific IgG2c-
producing LLPCs in the bone marrow (Fig. 6, A and B). Exami-
nation of MBCs in the spleen and MedLN reveal comparable fre-
quencies of total influenza-specific IgG MBCs (Fig. 6C). These
results clearly indicate that, with the exception of the reduced
FIGURE 6. Immune influenza-specific IgG responses. A, Influenza-spe-
cific IgG isotypes from day 180 sera samples of B6 or ST6Gal I/ mice.
B, ELISPOT assay was used to determine the virus-specific IgG1, IgG2b,
IgG2c, and IgG3 ASCs in bone marrow of mice (LLPCs). C, Memory B
cell numbers from spleen and MedLN; cells are pooled from four mice for
MedLN; n  4–8 mice/group.
FIGURE 7. Loss of expression of ST6Gal I by B cells results in defec-
tive influenza specific IgM. A, Cartoon depicting experimental protocol
where MT/ recipient mice were primed with 107.4 EID50 i.p; 90 days
later, 2  107 purified naive B220 B cells from B6 or ST6Gal I/ mice
were adoptively transferred i.v. into mice. Control mice received no trans-
ferred cells. Mice were infected with 106.8 EID50 influenza A/HKx31 in-
tranasally 1 day later and bled on indicated days. Serum virus-specific Abs
for IgM (B) or IgG (C) levels were detected by ELISA, n  3 mice in each
group.
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IgG2c levels, immune ST6Gal I/ mice generated similar high
titers of antiviral-specific Ab.
B cell expression of ST6Gal I is required to generate optimal
levels of viral-specific IgM
Our data indicate that ST6Gal I/ mice are able to generate
strong antiviral humoral memory despite early impairments in the
generation of the viral-specific humoral response (Figs. 2 and 6).
To determine whether it is the expression of ST6Gal I by B cells
alone that results in impairment of the early antiviral IgM and IgG
response, we transferred purified naive B cells from either wild-
type or ST6Gal I/ mice into primed B cell-deficient MT/
mice. Recipient mice were intranasally infected with influenza and
serially bled to determine influenza-specific Ab levels. Mice that
received ST6Gal I/ B cells show impaired influenza-specific
IgM levels but similar viral-specific IgG (Fig. 7). These data argue
that the observed impairment in production of viral-specific IgM in
ST6Gal I/ mice is likely B cell intrinsic; however, the impair-
ment in early production of viral-specific IgG is not B cell intrin-
sic. Thus, expression of ST6Gal I by B cells, at least in part, is
required for normal antiviral humoral immunity.
Discussion
In this article, we have evaluated the influence of posttranslational
modification of glycoproteins on the immune response to influenza
virus infection. Changes in the posttranslational modification of
glycoproteins during immune responses have been reported for
decades, but their functional importance remains obscure (24–32).
We demonstrate that in contrast to observations with PNA lectin
binding, which changes during activation/differentiation of B cells,
naive and activated B cells in vivo show similar high binding of
SNA (Fig. 1). This supports recently published data showing that
ST6Gal I gene expression does not change following B cell acti-
vation in vitro (13). Using ST6Gal I/ mice, which lack the abil-
ity to catalyze the addition of 2,6 sialic acids to N-linked glyco-
proteins, we investigated the role of this modification on the
generation of an influenza-specific humoral response. Serum levels
of influenza-specific Abs in these mice are reduced early in the
immune response, with influenza-specific IgM responses showing
the greatest impairment (Fig. 2A). These data are supported by
reductions in the frequencies of viral-specific plasma cells, sug-
gesting that the impaired viral-specific Ab levels are likely a result
of altered generation of short-lived viral-specific plasma cells and
not a result of preferential scavenging of Abs lacking 2,6 sialic
acids (Figs. 2C and 3C). Additionally, ST6Gal I/ mice show no
differences in influenza viral replication in the lungs, so the re-
duced Ab levels are not due to reduced viral load or Ag availability
in these mice (Fig. 4). We did observe comparable influenza-spe-
cific CD4 and CD8 T cell responses in the lung and draining lymph
nodes of these mice, and this most likely explains why ST6Gal
I/ mice are able to control and clear influenza viral infection in
the lungs by day 10, similar to wild-type mice (Fig. 5). Despite
significant impairments in the generation of an early antiviral hu-
moral response, ST6Gal I/ mice are able to generate potent
antiviral humoral immunity, with high levels of class-switched IgG
Abs by day 14 and memory time points (Figs. 2A and 6). This is
the first reported analysis of antiviral immune responses in ST6Gal
I/ mice.
To determine whether the observed impairment of antiviral hu-
moral responses were B cell intrinsic, we adoptively transferred
ST6Gal I/ or ST6Gal I/ B cells into primed B cell-deficient
MT/ mice (Fig. 7). Primed mice were used to ensure adequate
CD4 T help in these mice. The antiviral IgM response to infection
was substantially impaired in mice that received ST6Gal I/ B
cells. However, the antiviral IgG response was similar compared
with mice that received wild-type B cells. These results suggest
that the defective antiviral IgM response observed in ST6Gal I/
mice is likely B cell intrinsic. While we must be cautious with our
interpretations of antiviral responses in B cell-deficient mice due to
known alterations in lymphoid architecture, the results raise the
possibility that subtle defects in an additional cell compartment in
ST6Gal I/ mice may contribute to the delayed antiviral IgG
response. Future studies will investigate how ST6Gal I deficiency
affects other lymphoid cells and how this loss contributes to the
defective antiviral response.
Recent reports have demonstrated that loss of expression of
ST6Gal I by B cells results in preferential colocalization of the
BCR with CD22, a negative regulator of BCR signaling, in clath-
rin-rich membrane microdomains (6, 15). Aged CD22-deficient
mice have been reported to develop IgM autoantibodies (33). Ab-
lation of CD22 expression in ST6Gal I/ mice rescues BCR sig-
naling defects (6). In naive B cells, modification of CD22 by
ST6Gal I normally results in segregation of CD22 molecules, due
to homotypic interactions with the 2,6 sialic acid cis-ligands of
other CD22 molecules (6). Following Ag receptor engagement,
CD22 is tyrosine phosphorylated, and phosphorylated CD22 re-
cruits SHP-1 (Src homology domain2-containing tyrosine phos-
phatase), mediating signal inhibition via the BCR (33, 34). Due to
the absence of these cis-CD22 ligands in ST6Gal I/ mice, there
is increased association of sIgM with the inhibitory receptor CD22
on naive B cells; following Ag receptor engagement in vivo, this
could result in immediate attenuated BCR signaling. We speculate
that a possible in vivo outcome of this could be significantly im-
paired differentiation of naive B cells into extrafollicular short-
lived plasma cells following viral infection of ST6Gal I/ mice
(33, 35–38). Viral-specific B cells in the ST6Gal I/ mice, with
“weak or moderate BCR” signaling could enter germinal centers
and undergo affinity maturation and differentiation into plasma
cells. This could explain why we observe that after day 14 p.i.,
influenza-specific IgG responses are quite comparable to wild-type
mice. Thus, in a normal immune response, ST6Gal I modification
of glycoproteins on naive B cells may influence the signaling
threshold required following Ag receptor signaling, and the bio-
logical outcome in vivo would favor differentiation of a greater
proportion of Ag-specific B cells into extrafollicular short-lived
plasma cells, important in the early control of pathogens. Alterna-
tively, the repertoire of B cells available in ST6Gal I/ mice
could be different from wild-type mice due to differences in sig-
naling strength during development (39, 40).
In conclusion, our data demonstrate that despite early defects in
the generation of an antiviral humoral response, ST6Gal I/ mice
are able to clear virus and generate potent humoral memory. Fur-
thermore, our data suggest that loss of ST6Gal I expression by B
cells may be responsible for the impaired antiviral IgM response.
Finally, loss of expression of ST6Gal I in non-B cells likely con-
tributes to the impaired IgG humoral response. Future experiments
will elucidate how the expression of this enzyme, by different lym-
phocyte populations, influences the generation of an antiviral im-
mune response.
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